Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- JPM identifies consumer sectors to buy for a 2H rebound
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Esperion Therapeutics (ESPR) Tops Q1 EPS by 11c
May 3, 2022 7:16 AM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $15.39 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
... More